Life Science

BIOSILICO: Pharma at a crossroads

A subtext of BIOSILICO was the business conditions of Big Pharma, the giant corporations that produce the , Zocors, Celebrexs, and Gleevecs of the health system. The pharmaceutical companies are the direct customers for many of the tools and research approaches of bioinformatics and in silico biology. Many speakers represented companies that are producing hardware and/or software for which the ...

Read More »

Enhancement

Here’s a commentary by Gregory Stock, a UCLA geneticist who insists that our medical future includes not just fixing sick people but enhancing well people too. His comment is about the approval by the FDA of using growth hormone to increase the growth of children whose bodies already produce normal growth hormone. Initially the hormone was approved only for kids ...

Read More »

Biosilico 2003: The Data Tsunami

We seem to be heading for vocabulary exhaustion. In a time when “extreme” is a common marketing adjective we’re running out of superlatives. So the term “tsunami”—the biggest of all waves—was used at BIOSILICO to describe the rate of data generation in life science. And just as a tsunami slamming the coastline is a big problem, the wealth of data ...

Read More »

Biosilico 2003

Thanks to the FI Center I was able to attend a conference at Stanford a little while ago called BIOSILICO 2003 organized by Scientific American. It’s taken me a while to let the deluge of technical information and bioinformatics industry insider-jargon settle into a few themes that I can pull together. Over the next few days I’d like to recap ...

Read More »